ArticleAbdominal radiology (New York)2026
Contrast-enhanced MRI for identifying the steatohepatitic hepatocellular carcinoma from small hepatocellular carcinoma.
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAims to evaluate the potential of contrast-enhanced magnetic resonance imaging (MRI) in distinguishing steatohepatitic hepatocellular carcinoma (SH-HCC) from small(diameter < 2 cm) non-otherwise specified hepatocellular carcinoma.
methodsThis retrospective study included 32 patients with SH-HCC and 241 patients with sNOS-HCC who underwent resection between January 2017 and June 2022. The clinical, pathological, and MRI features of these patients were compared. Logistic regression analysis was employed to identify independent predictors of SH-HCC and to develop a nomogram for differentiating SH-HCC from sNOS-HCC. Model discrimination was assessed by calculating the area under the ROC curve (AUC), while calibration curves and decision curve analysis (DCA) were performed to evaluate calibration accuracy and clinical utility, respectively.
resultsUnivariate and multivariate analyses identified T2DM (OR = 3.025; 95%CI:1.059, 8.634; p = 0.039), HBV infection (OR = 0.293; 95%CI:0.095, 0.900; p = 0.032), elevated TBil (OR = 1.065; 95%CI: 1.015, 1.117; p = 0.010), T1WI opposed-phase signal drop (OR = 4.217; 95%CI: 1.177, 15.107; p = 0.027), and diffuse intratumoral fat (OR = 6.255; 95%CI: 2.024, 19.337; p = 0.001) as independent predictors for SH-HCC. These five variables were used to establish the nomogram, which had a C-index of 0.873 (95% CI: 0.844-0.902). The ROC analysis revealed that the AUC of this model was 0.886, with a sensitivity of 84.4% and a specificity of 84.3%. It not only demonstrated excellent discriminatory ability but also had a high negative predictive value (NPV = 97.6%).
conclusionThe integration of MRI imaging features-specifically, diffuse intratumoral fat and T1WI opposed-phase signal drop-with key clinical factors, including T2DM, HBV infection, and elevated TBil, demonstrates robust diagnostic performance in the preoperative differentiation of SH-HCC from sNOS-HCC. This multimodal model not only achieves high discriminatory accuracy but also yields a markedly high negative predictive value.
Indexed as
Identifiers
41207885What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.